Vidac Pharma Holding PLC: Vidac Pharma Strengthens Market Liquidity While Advancing Clinical Pipeline

Shareholders and management to enhance free float and reinvest proceeds to accelerate development

London (pta024/17.12.2025/12:38 UTC+1)

Vidac Pharma Holdings Plc. is grateful to its shareholders for their continued support of the Company.

As Vidac Pharma closes 2025 on a strong and positive note, marked by the approved and initiated Phase 2 clinical trial in actinic keratosis (AK), the Company is pleased to share its outlook for 2026. The main shareholders and Managing Directors of the Company intend to enhance the Company's free float and market liquidity by selling a portion of their personal shareholdings at market price. The net proceeds from these sales are planned to be reinvested into the Company to accelerate the development of its projects and clinical programs.

These steps, together with the recent integration of trading on XETRA (Deutsche Börse), demonstrate the Managing Directors' confidence in Vidac Pharma's growth trajectory, clinical strategy, and the value creation potential envisioned for the coming year.

"The approval and initiation of our Phase 2 clinical trial, together with our recent entry onto XETRA, represent important milestones for Vidac Pharma," said Dr. Max Herzberg, Chief Executive Officer of Vidac Pharma. "As we move into 2026, management's planned reinvestment reflects our strong belief in the Company's strategy and our commitment to advancing our pipeline and delivering long-term value to shareholders."

Vidac Pharma looks ahead to 2026 with confidence and wishes all shareholders, partners, and stakeholders a very successful new year.

(end)

Emitter:	Vidac Pharma Holding PLC 20-22 Wenlock Road N1 7GU London United Kingdom
Contact Person:	Sandra Gamzon
Phone:	+972 544 999951
E-Mail:	investors@vidacpharma.com
Website:	www.vidacpharma.com
ISIN(s):	GB00BM9XQ619 (Share)
Stock Exchange(s):	Free Market in Berlin, Dusseldorf (Primärmarkt), Hamburg, Stuttgart